862P Neoadjuvant Chemo-Immunotherapy Using Carboplatin, Nab-Paclitaxel, Oral Metronomic Therapy and Low Dose Nivolumab for “borderline Resectable” Oral Cavity Carcinoma: A Prospective Phase II Single-Arm Trial (Neolocus)
Annals of Oncology(2024)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要